MACAO, May 31, 2026 /PRNewswire/ — The BEYOND Expo 2026 has shown what the future looks like as it delivers on its mission of ‘Empowering Asia, Bridging the World’ with a heavyweight showcase of the latest emerging technology and ideas from Asia. Held at The Venetian Cotai Expo with the theme “AI: Digital to Physical” the expo focuses on bringing AI from digital to the physical world. With the launch of many new products, nearly 800 exhibitors, the focus is on embodied intelligence, robotics, spatial computing, AI agents, open ecosystems, and global capital. For the first time, the expo features smaller innovative entities such as OPCs (one-person companies), allowing independent entrepreneurs and individual creators to showcase their work alongside leading brands.

Following an Opening Ceremony that attracted over 1,000 guests from China, the EU, Middle East, Southeast Asia, South America, UK, US and other countries, the show has already attracted high level visitors, including corporate executives, entrepreneurial leaders, investors, local government representatives, international partners. Over 500 international and leading tech media from all over the world have also joined creating a global innovation exchange platform that transcends regions, industries, and ecosystems.

At the opening ceremony, Jason Ho, co-founder of BEYOND Expo explained “BEYOND Expo aims to connect Asian innovation with global partners, creating more opportunities for exchange in technology, investment, sports, and entertainment. We don’t just have brilliant software companies building AI models; we have the powerhouse factories, advanced hardware innovators, and the infrastructure that actually gives AI its physical body. That is why we believe Asia is where BEYOND belongs. From next-gen chips to Physical AI, we don’t just design the digital future-we actually manufacture it.”

Setting the tone for BEYOND Expo, the Opening Ceremony speakers included Deepu Talla, Vice President Robotics & Edge AI at NVIDIA; Mark Nicholas Cutis, Senior Advisor for Strategic Projects in the Office of the Managing Director and CEO at the Abu Dhabi Investment Committee (ADIC); Felix Zhang, Founder and CEO of Pudu Robotics; Chi Xu, Founder and CEO of XREAL; and Matt White, Global Chief Technology Officer for AI at the Linux Foundation.

BEYOND Expo 2026 is moving into its last day following two days packed with keynotes and panel discussions across seven main stages. Summits included BGlobal Summit, International Investment and Financing Summit, Physical AI Summit, Digital AI Summit, Japan Technology Forum, Korea Technology Forum, Asia -Europe Technology Forum, Asia-Latin America Technology Forum, SheTech Women’s Technology Summit, Web2+3 Summit, AI Beauty & Health Summit, as well as business matchmaking sessions, BEYOND Awards, and BEYOND HACK DAY, covering areas such as technology demonstrations, industry exchanges, cross-regional cooperation, investment and financing matchmaking, developer ecosystem, and innovative project showcases.

From the technological evolution of physical AI to the industrial application of embodied intelligence, and further to the participation of spatial computing, AI agents, global capital, developer ecosystems, and cross-regional cooperation, BEYOND Expo 2026 explores the digital to physical from multiple dimensions. Artificial intelligence is moving from screens, text, and cloud models to robots, wearable devices, spatial computing, industrial systems, and real-world execution.

Visit BEYOND Expo 2026 at The Venetian  Macao’s Cotai Expo

BEYOND Expo 2026 is being held at The Venetian Macao’s Cotai Expo. As Macao’s largest integrated resort operator, Sands China has an extensive range of MICE offerings across its properties: The Venetian^® Macao, The Parisian^® Macao, and The Londoner^® Macao. Sands Lifestyle provides a one-stop destination offering, seven Forbes five-star hotels accommodation, world-class entertainment venues, spectacular recreation and leisure options, unrivalled shopping experiences and dynamic dining options, attracting top event planners from around the world to host major events here.

A full list of participating companies can be found here: Beyond Expo 2026 Exhibitors

-ends-

About BEYOND Expo

The BEYOND International Technology Innovation Expo (BEYOND Expo) is Asia’s leading annual technology event. Serving as a dynamic platform since 2021, BEYOND Expo not only showcases global technological innovations but also provides a unique opportunity to foster innovation upgrades across diverse industries and regions.

BEYOND Expo has attracted participation from Asia’s Fortune 500 companies, multinational corporations, unicorn companies, and emerging startups. Through a multifaceted approach involving expos, summits, and various activities, BEYOND Expo has successfully cultivated an innovative ecosystem, propelling collective development in the Asia-Pacific region and the global technology innovation industry. www.beyondexpo.com

SHANGHAI, May 31, 2026 /PRNewswire/ — The 28th Shanghai International Film Festival (SIFF) has officially unveiled the competition selections for the 2026 Golden Goblet Awards.

Held from June 12 to 21, the Festival received approximately 4,100 submissions from 125 countries and regions this year, setting a new historical record. According to the Festival, around 3,000 films met the eligibility requirements for competition, while 82% of the submitted entries are world or international premieres. The Festival also expanded its reach with first-time submissions from countries including Ghana and Mozambique.

Notably, all 12 films selected for the Golden Goblet Main Competition will make their world premieres in Shanghai. This marks the first time in the history of the Golden Goblet Awards that the Main Competition has achieved a 100% world-premiere lineup, underscoring Shanghai’s growing appeal as a launch platform for filmmakers from around the world.

The Golden Goblet Awards remain the centerpiece of SIFF’s international competition program, covering Main Competition, Asian New Talent, Documentary, Animation, and Short Film sections.

MAIN COMPETITION

ATLANTIC RHAPSODY
Director: ZHONG Kaifeng
（China）

HALIMA
Director: Yassine El Idrissi
（Morocco）

ILUMINADA
Director: Nicolás Rincón Gille
（Belgium）

LUIZA’S DESERT
Director: Alan Minas
（Brazil, United Kingdom）

MY OWN LAST SUPPER
Director: ismail BASBETH
（Indonesia）

NIGHT OF BLINDNESS
Director: Reis Çelik
（Turkey, Germany）

SEA SONS
Director: Daniil Merkulov
（Russia）

SECRET IN THE BOX
Director: Frankie Tam Kwong Yuen
（Chinese Mainland, Hong Kong China）

SUPERBUHEI
Director: Josef Brandl
（Germany）

THE GREAT SKULL
Director: LIU Xiaoyang
（China）

THE MISERABLE MOTHER
Director: Susanne Heinrich
（Germany, France）

THE PARKING SPOT
Director: Louis Godbout
（Canada）

ASIAN NEW TALENT

9 TEMPLES TO HEAVEN
Director: Sompot Chidgasornpongse
（Thailand）

ABOUT THE MOTHER
Director: Büşra Bülbül
（Turkey）

BOOMAH
Director: Zaid Abu Hamdan
（Jordan, Saudi Arabia）

CASSOWARY
Director: ZHANG Hanyi
（China）

DOG DAY EVENING
Director: Mak Tin Shu
（Chinese Mainland, Hong Kong China）

HER FIRST TASTE
Director: GONG Yiwen
（China）

HUNTER’S MOON
Director: Ridham Janve
（India, Germany）

NO GOOD IN SIGHT: A STORY
Director: Alibi Mukushev
（Kazakhstan）

NO HARD FEELINGS
Director: LIU Shichuan
（China）

SKYLARK
Director: Narghiza Dotieva
（Kyrgyzstan）

STRANGERS IN THE MOUNTAIN
Director: WAN Bo
（China）

THE BLIND GIRL AND AN ELEPHANT
Director: Ishtiyak Ahmad Zihad
（Bangladesh, Germany）

DOCUMENTARY

BENIGNO
Director: David Baute
（Spain）

NOTES UNHEARD
Director: GU Yun
（China）

RUINS
Director: Elena Chemerska
（North Macedonia, Croatia, Slovenia）

THE TIGER OF THE EAST
Director: Jorge Acevedo
（Chile）

WHEELS OF FORGOTTEN DREAMS
Directors: Milos Ljubomirovic, Danilo Lazovic
（Serbia, Bulgaria, Croatia）

ANIMATION

AMADEO AND THE HYPOTHETICAL NEW WORLD
Directors: Brenda Lígia, Edu Felistoque
（Brazil）

DANTE
Director: Linda Hambäck
（Sweden, Norway, Denmark）

GARUDA: DARE TO DREAM
Director: Ronny Gani
（Indonesia）

LUCY LOST
Director: Olivier Clert
（France）

WINNIPEG, SEEDS OF HOPE
Directors: Elio Guiroga, Beñat Beitia
（Spain, Chile, Argentina ）

SHORT FILM (LIVE ACTION)

2000
Director: Renata Lučić
（Croatia）

CHICKEN LADY
Director: YUAN Shuqi
（China, USA）

ELSEWHERE
Director: LIN Tingxuan
（China, Thailand）

KILL, KOKESH, KILL!
Director: Jan Míka
（Czech Republic）

LAST TRAIN
Director: XU Weihao
（China）

LAZARE
Director: Claire Dietrich
（France）

SITTING BIRD
Director: Athena Han
（Canada）

THE DROUGHT
Director: Cristian Popa
（Romania）

THE MATCHMAKER
Director: Sophia Kuestenmacher
（Germany）

ZAZA GOGOGO
Director: CHEN Kedi
（China）

SHORT FILM (ANIMATED)

IF ONLY
Director: Ada Guvenir
（Belgium）

JULKA
Director: Valeria Cozzarini
（Slovenia, Italy）

SHOES
Director: Salvatore Centoducati
（Italy）

UNPLUG
Director: Comandante Bebé
（Spain）

WATER’S TIME SLICE
Director: HE Jiaxuan
（China）

Hong Kong actor Tony Leung Chiu-wai serves as President of the Main Competition Jury, while Singaporean filmmaker Anthony Chen chairs the Asian New Talent section. Documentary filmmaker Geeta Gandbhir heads the Documentary Jury, British animator Will Becher leads the Animation Jury, and Portuguese filmmaker João Salaviza serves as President of the Short Film Jury.

This year’s Festival will present more than 420 international films across over 1,500 screenings throughout Shanghai.

• Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third-generation EGFR TKI
• In treatment-naïve patients with advanced NSCLC without driver mutations, Golidocitinib, a JAK-only inhibitor, in combination with anti-PD-1 antibody enhanced anti-tumor response. 

SHANGHAI, May 31, 2026 /PRNewswire/ — Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of oncology and hematological diseases, today announced the presentations of two studies in non-small cell lung cancer (NSCLC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. One study evaluated DZD6008, an investigational fourth-generation EGFR TKI, in pre-treated NSCLC patients with EGFR C797X mutations following progression on third-generation EGFR TKI treatment. The results were featured in an oral presentation. The other study reported results for golidocitinib, a JAK1-selective inhibitor, combined with an anti-PD-1 antibody as a first-line treatment for PD-L1-positive, advanced NSCLC without driver mutations.

DZD6008: A Fourth-Generation EGFR TKI Overcomes Resistance Following Third-Generation EGFR TKI Failure

The latest findings showed that DZD6008 demonstrated strong and durable anti-tumor activity in patients relapsed from third-generation EGFR TKI with a favorable safety profile.

• The majority of patients (82.1%) had tumor shrinkage following DZD6008 treatment. Higher response rate is expected with longer treatment.
• Tumor response is durable, with 6 months progression free survival (PFS) rates at 70.6% and 61.8%, respectively for 40 mg and 60 mg cohorts. The median duration of response (DoR) was not reached.
• Excellent blood-brain barrier (BBB) penetration was observed, including strong intracranial anti-tumor activity among patients with baseline brain metastasis.
• DZD6008 demonstrated a favorable safety profile with high selectivity for wild-type EGFR, resulting in minimal adverse effects.

Patients with EGFR-mutant NSCLC whose disease progresses on or after third-generation EGFR TKI treatment often acquire resistance mutations, among which EGFR C797X is one of the most frequently reported. DZD6008 is a fourth-generation EGFR TKI designed with full BBB penetration and high selectivity over wild-type EGFR. Preclinical and clinical data support its potent activities against single, double and triple EGFR mutations (L858R/19del, T790M, C797X).

Golidocitinib: A JAK1 Inhibitor Combined with Anti-PD-1 Demonstrates Durable Clinical Benefit

Among 47 enrolled treatment-naïve patients with advanced NSCLC, golidocitinib plus sintilimab following chemo-immunotherapy demonstrated encouraging and durable anti-tumor efficacy, particularly in those with high PD-L1 expression. Profound improvement of irAE was noticed.

Dr. Xiaolin Zhang, CEO of Dizal, said: “Main reasons for patients relapsed from 3^rd generation EGFR TKI treatment include acquired resistance mutations and CNS metastasis. DZD6008 was designed to address these clinical issues. The data presented confirmed that DZD6008 met our design criteria and has the potential to provide an oral safe treatment option for these patients. We are very excited by the clinical data. We look forward to collaborating with investigators worldwide to accelerate its clinical development globally.”

About Golidocitinib (DZD4205)

Golidocitinib is currently the first and only Janus kinase 1 (JAK1) inhibitor being evaluated for the treatment of r/r PTCL. In June 2024, golidocitinib was approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL).

At the data cut-off date of August 31, 2023, golidocitinib has demonstrated robust and durable anti-tumor efficacy, with an ORR of 44.3%. All subtypes benefited well, and the ORR of common subtypes exceeded 40%. More than 50% of the patients with tumor remission achieved a complete response with a CRR of 23.9%. Per IRC assessment, the median duration of response (mDoR) reached 20.7 months. As of February 2024, golidocitinib showed a median overall survival (mOS) of 24.3 months.

Golidocitinib was granted Fast Track Designation by the U.S. FDA for the treatment of r/r PTCL in February 2022. In September 2023, the CDE accepted its NDA and granted Priority Review for the treatment of r/r PTCL. The Phase I clinical data of golidocitinib (JACKPOT8 PART A) were published in Annals of Oncology (Impact Factor: 51.8), and global pivotal trial data of golidocitinib for the treatment of r/r PTCL (JACKPOT PART B) were published in The Lancet Oncology (Impact Factor: 54.4).

About DZD6008

DZD6008 is a novel, highly selective, full-BBB penetrant EGFR TKI, designed as a potential treatment option for advanced EGFR mutation positive (EGFRm) NSCLC.

Non-small cell lung cancer is the leading cause of cancer death in the world. Epidermal growth factor receptor (EGFR) gene is one of the most common driver genes for NSCLC. Multiple agents can be used to treat patients with EGFR mutated NSCLC who develop resistance to EGFR tyrosine kinase inhibitors (TKIs), but the clinical outcome was not satisfactory. Brain metastases (BM) are a leading cause of death and disease progression for NSCLC. Approximately 23%-30% of NSCLC patients are synchronous BM at their initial diagnosis. Previous studies reported that the 3-year cumulative rate of BMs ranges from 29.4% to 60.3% in patients with mutated EGFR.

Currently, the clinical benefits of existing treatments for third-generation EGFR TKI-resistant NSCLC are limited and DZD6008 is expected to fill the unmet medical needs. DZD6008 effectively inhibits EGFR-mutated tumor growth in cell lines and in animal models. Previous clinical studies have validated the design concept of the molecule and suggest that DZD6008 demonstrates good safety and efficacy in NSCLC patients with brain metastases who had failed third-generation EGFR TKI therapy or multiple lines of pre-treatments.

About Dizal

Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases. The company aims to develop first-in-class and groundbreaking new medicines, and further address unmet medical needs worldwide. Deep-rooted in translational science and molecular design, it has established an internationally competitive portfolio with multiple assets in global pivotal studies and two leading assets: ZEGFROVY, approved in both the U.S. and China, and golidocitinib, approved in China. To learn more about Dizal, please visit www.dizalpharma.com, or follow us on LinkedIn or X.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, and “intend” and similar expressions, as they relate to Dizal, are intended to identify certain forward-looking statements. Dizal does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections, and understandings of the management of Dizal with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond Dizal’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Dizal’s competitive environment, and political, economic, legal, and social conditions.

Dizal, the Directors, and the employees of Dizal assume (a) no obligation to correct or update the forward-looking statements contained on this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turnout to be incorrect.

Contacts

Investor Relations: ir@dizalpharma.com
Business Development: bd@dizalpharma.com
Media Contact: pr@dizalpharma.com

CHENGDU, China, May 31, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”, 6990.HK) announced today that the results of the Phase III clinical study OptiTROP-Lung05, evaluating the company’s trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870)(佳泰莱^®) in combination with pembrolizumab (KEYTRUDA^®[1], MSD’s anti-programmed cell death protein 1 (PD-1) antibody) as first-line treatment for Programmed Death-Ligand 1 (PD-L1) Tumor Proportion Score (TPS)≥1% non-small cell lung cancer (NSCLC), have been published in the prestigious international medical journal The Lancet (IF=88.5)^[2]. The co-senior authors are: Professor Caicun Zhou from Shanghai East Hospital, Tongji University; and Dr. Junyou Ge, Director of the National Engineering Research Centre of Targeted Biologics. The co‑first authors are: Professor Anwen Xiong from Shanghai East Hospital, Tongji University; Professor Wenxiu Yao from Sichuan Cancer Hospital; Professor Wei Zheng from Shengjing Hospital, China Medical University; Professor Yan Yu from Harbin Medical University Cancer Hospital; Professor Peng Chen from Tianjin Medical University Cancer Institute and Hospital; Professor Hua Zhong from Shanghai Chest Hospital; and Dr. Junyou Ge, Director of the National Engineering Research Centre of Targeted Biologics. The study findings were also selected for an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #8506, Lung Cancer – Metastatic Non-Small Cell).

OptiTROP-Lung05 is a randomized, open-label, multicenter Phase III clinical study designed to evaluate the efficacy and safety of sac-TMT in combination with pembrolizumab versus pembrolizumab alone as first-line treatment for patients with locally advanced or metastatic PD-L1 TPS≥1% NSCLC.

The interim analysis results show that compared with pembrolizumab monotherapy, the combination of sac-TMT and pembrolizumab significantly prolongs progression-free survival (PFS) and reduces the risk of disease progression or death, with a hazard ratio (HR) of 0.35. Consistent PFS benefits were observed across all prespecified subgroups, including by PD-L1 expression level and histological type, with PFS HRs of 0.47 and 0.28 for the PD-L1 TPS ≥50% and 1–49% subgroups, respectively, and PFS HRs of 0.28 and 0.44 for the non-squamous and squamous subgroups, respectively. A positive trend in overall survival (OS) was also observed, with an HR of 0.55. Furthermore, the overall safety profile of sac-TMT in combination with pembrolizumab was manageable, consistent with the established safety profiles of sac-TMT alone or pembrolizumab alone, and no new safety signals identified.

This is the first Phase III trial of an ADC combined with an immune checkpoint inhibitor to meet its primary endpoint in the first line treatment of NSCLC, and for the first time demonstrate that “ADC+IO” combination of sac-TMT plus pembrolizumab has the potential to achieve survival benefit as first‑line therapy for NSCLC. The publication of these findings in The Lancet further signifies that the clinical and academic value of this combination therapy has received internationally recognized validation.

About sac-TMT(佳泰莱^®)

Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors and genitourinary tumors, among others. Sac-TMT is developed with a unique, bifunctional linker that maximizes payload delivery to tumor cells both through its irreversible connection with the anti-TROP2 monoclonal antibody sacituzumab and its pH-sensitive cleavage from a belotecan-derivative topoisomerase I inhibitor payload in the lysosome, with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macao and Taiwan).

To date, four indications for sac-TMT have been approved and marketed in China for: 1) unresectable locally advanced or metastatic triple‑negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting); 2) EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy and platinum-based chemotherapy; 3) epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy; 4) unresectable or metastatic hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) (Immunohistochemistry (IHC) 0, IHC 1+ or IHC 2+/In Situ Hybridization (ISH)-) BC who have received prior endocrine therapy and at least one line of chemotherapy in advanced setting. The first two indications above have been included in China’s National Reimbursement Drug List (NRDL). This inclusion is expected to bring clinically meaningful benefits to a greater number of patients with BC and NSCLC. Additionally, sac-TMT has been granted six Breakthrough Therapy Designations (BTDs) by the National Medical Products Administration (NMPA).

Sac-TMT is the world’s first TROP2 ADC drug approved for marketing in lung cancer. A new indication application for sac-TMT in combination with pembrolizumab (KEYTRUDA^®) as first‑line treatment for locally advanced or metastatic NSCLC who have PD-L1 TPS≥1% and are EGFR-negative and anaplastic lymphoma kinase (ALK)-negative has been accepted for review by the NMPA, and has entered the priority review and approval process. As of today, Kelun-Biotech has initiated 9 registrational clinical studies in China. MSD is evaluating 17 ongoing global Phase III clinical studies of sac-TMT as a monotherapy or in combination with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects have been approved for marketing, 1 project is in the new drug application (NDA) stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world’s leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.